Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regenxbio (RGNX) Depreciation & Amortization (CF) (2016 - 2025)

Historic Depreciation & Amortization (CF) for Regenxbio (RGNX) over the last 11 years, with Q3 2025 value amounting to $3.9 million.

  • Regenxbio's Depreciation & Amortization (CF) fell 189.35% to $3.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.8 million, marking a year-over-year decrease of 458.64%. This contributed to the annual value of $16.2 million for FY2024, which is 637.99% down from last year.
  • According to the latest figures from Q3 2025, Regenxbio's Depreciation & Amortization (CF) is $3.9 million, which was down 189.35% from $3.9 million recorded in Q2 2025.
  • Regenxbio's Depreciation & Amortization (CF)'s 5-year high stood at $4.4 million during Q2 2023, with a 5-year trough of $1.9 million in Q1 2021.
  • In the last 5 years, Regenxbio's Depreciation & Amortization (CF) had a median value of $4.0 million in 2025 and averaged $3.6 million.
  • Per our database at Business Quant, Regenxbio's Depreciation & Amortization (CF) surged by 6780.17% in 2023 and then plummeted by 940.07% in 2024.
  • Over the past 5 years, Regenxbio's Depreciation & Amortization (CF) (Quarter) stood at $2.6 million in 2021, then surged by 56.17% to $4.1 million in 2022, then increased by 5.07% to $4.3 million in 2023, then decreased by 7.2% to $4.0 million in 2024, then decreased by 3.41% to $3.9 million in 2025.
  • Its last three reported values are $3.9 million in Q3 2025, $3.9 million for Q2 2025, and $4.0 million during Q1 2025.